<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Europace</journal-id>
    <journal-id journal-id-type="iso-abbrev">Europace</journal-id>
    <journal-id journal-id-type="publisher-id">europace</journal-id>
    <journal-title-group>
      <journal-title>Europace</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1099-5129</issn>
    <issn pub-type="epub">1532-2092</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
      <publisher-loc>US</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10103564</article-id>
    <article-id pub-id-type="pmid">36006664</article-id>
    <article-id pub-id-type="doi">10.1093/europace/euac145</article-id>
    <article-id pub-id-type="publisher-id">euac145</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Clinical Research</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Ablation for Atrial Fibrillation</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/MED00200</subject>
      </subj-group>
      <subj-group subj-group-type="category-oup-series">
        <subject>Editor's Choice</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>AFA-Recur: an ESC EORP AFA-LT registry machine-learning web calculator predicting atrial fibrillation recurrence after ablation</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9475-1507</contrib-id>
        <name>
          <surname>Saglietto</surname>
          <given-names>Andrea</given-names>
        </name>
        <aff><institution>Division of Cardiology, Department of Medical Sciences, ‘Città della Salute e della Scienza di Torino’ Hospital, University of Turin</institution>, <addr-line>Turin</addr-line>, <country country="IT">Italy</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3178-6205</contrib-id>
        <name>
          <surname>Gaita</surname>
          <given-names>Fiorenzo</given-names>
        </name>
        <aff><institution>Cardiology Unit, J Medical</institution>, <addr-line>Turin</addr-line>, <country country="IT">Italy</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2806-3903</contrib-id>
        <name>
          <surname>Blomstrom-Lundqvist</surname>
          <given-names>Carina</given-names>
        </name>
        <aff><institution>Department of Medical Science and Cardiology, Uppsala University</institution>, <addr-line>Uppsala</addr-line>, <country country="SE">Sweden</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0424-6393</contrib-id>
        <name>
          <surname>Arbelo</surname>
          <given-names>Elena</given-names>
        </name>
        <aff><institution>Department of Cardiology, Cardiovascular Institut, Hospital Clinic de Barcelona, Universitat de Barcelona</institution>, <addr-line>Barcelona</addr-line>, <country country="ES">Spain</country></aff>
        <aff><institution>Institut d’Investigació August Pi iSunyer (IDIBAPS)</institution>, <addr-line>Barcelona</addr-line>, <country country="ES">Spain</country></aff>
        <aff><institution>Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV)</institution>, <addr-line>Madrid</addr-line>, <country country="ES">Spain</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0323-4956</contrib-id>
        <name>
          <surname>Dagres</surname>
          <given-names>Nikolaos</given-names>
        </name>
        <aff><institution>Department of Electrophysiology, Heart Center Leipzig at University of Leipzig</institution>, <addr-line>Leipzig</addr-line>, <country country="DE">Germany</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5662-8302</contrib-id>
        <name>
          <surname>Brugada</surname>
          <given-names>Josep</given-names>
        </name>
        <aff><institution>Hospital Clínic Pediatric Arrhythmia Unit, Cardiovascular Institute, Hospital Sant Joan de Déu University of Barcelona</institution>, <addr-line>Barcelona</addr-line>, <country country="ES">Spain</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2764-6779</contrib-id>
        <name>
          <surname>Maggioni</surname>
          <given-names>Aldo Pietro</given-names>
        </name>
        <aff><institution>EURObservational Research Programme (EORP), European Society of Cardiology</institution>, <addr-line>Sophia-Antipolis</addr-line>, <country country="FR">France</country></aff>
        <aff><institution>ANMCO Research Centre</institution>, <addr-line>Florence</addr-line>, <country country="IT">Italy</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4448-5209</contrib-id>
        <name>
          <surname>Tavazzi</surname>
          <given-names>Luigi</given-names>
        </name>
        <aff><institution>Cardiovascular Department, Maria Cecilia Hospital, GVM Care &amp; Research</institution>, <addr-line>Cotignola</addr-line>, <country country="IT">Italy</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1632-6182</contrib-id>
        <name>
          <surname>Kautzner</surname>
          <given-names>Josef</given-names>
        </name>
        <aff><institution>Department of Cardiology, Institute for Clinical and Experimental Medicine (ΙΚΕΜ)</institution>, <addr-line>Prague</addr-line>, <country country="CZ">Czech Republic</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4940-0876</contrib-id>
        <name>
          <surname>De Ferrari</surname>
          <given-names>Gaetano Maria</given-names>
        </name>
        <aff><institution>Division of Cardiology, Department of Medical Sciences, ‘Città della Salute e della Scienza di Torino’ Hospital, University of Turin</institution>, <addr-line>Turin</addr-line>, <country country="IT">Italy</country></aff>
        <xref rid="euac145-cor1" ref-type="corresp"/>
        <!--gaetanomaria.deferrari@unito.it-->
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6311-4270</contrib-id>
        <name>
          <surname>Anselmino</surname>
          <given-names>Matteo</given-names>
        </name>
        <aff><institution>Division of Cardiology, Department of Medical Sciences, ‘Città della Salute e della Scienza di Torino’ Hospital, University of Turin</institution>, <addr-line>Turin</addr-line>, <country country="IT">Italy</country></aff>
        <on-behalf-of>on behalf of the AFA LT registry investigators group</on-behalf-of>
        <xref rid="euac145-FM1" ref-type="author-notes"/>
        <xref rid="euac145-FM10" ref-type="author-notes"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="euac145-cor1">Corresponding author. Tel: +39 01 1670 9596. <italic toggle="yes">E-mail address</italic>: <email>gaetanomaria.deferrari@unito.it</email></corresp>
      <fn id="euac145-FM1">
        <p>A complete list of the AFA-LT Investigators Group is provided in the Supplementary Material.</p>
      </fn>
      <fn id="euac145-FM10" fn-type="COI-statement">
        <p><bold>Conflict of interest:</bold> M.A. is consultant for Biosense Webster and Boston Scientific, proctor for Medtronic, and received educational support from Abbott.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-08-25">
      <day>25</day>
      <month>8</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>25</day>
      <month>8</month>
      <year>2022</year>
    </pub-date>
    <volume>25</volume>
    <issue>1</issue>
    <fpage>92</fpage>
    <lpage>100</lpage>
    <history>
      <date date-type="received">
        <day>12</day>
        <month>2</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>16</day>
        <month>7</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="euac145.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Aims</title>
        <p>Atrial fibrillation (AF) recurrence during the first year after catheter ablation remains common. Patient-specific prediction of arrhythmic recurrence would improve patient selection, and, potentially, avoid futile interventions. Available prediction algorithms, however, achieve unsatisfactory performance. Aim of the present study was to derive from ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry (AFA-LT) a machine-learning scoring system based on pre-procedural, easily accessible clinical variables to predict the probability of 1-year arrhythmic recurrence after catheter ablation.</p>
      </sec>
      <sec id="s2">
        <title>Methods and results</title>
        <p>Patients were randomly split into a training (80%) and a testing cohort (20%). Four different supervised machine-learning models (decision tree, random forest, AdaBoost, and <italic toggle="yes">k</italic>-nearest neighbour) were developed on the training cohort and hyperparameters were tuned using 10-fold cross validation. The model with the best discriminative performance on the testing cohort (area under the curve—AUC) was selected and underwent further optimization, including re-calibration. A total of 3128 patients were included. The random forest model showed the best performance on the testing cohort; a 19-variable version achieved good discriminative performance [AUC 0.721, 95% confidence interval (CI) 0.680–0.764], outperforming existing scores (e.g. APPLE score: AUC 0.557, 95% CI 0.506–0.607). Platt scaling was used to calibrate the model. The final calibrated model was implemented in a web calculator, freely available at <ext-link xlink:href="http://afarec.hpc4ai.unito.it/" ext-link-type="uri">http://afarec.hpc4ai.unito.it/</ext-link>.</p>
      </sec>
      <sec id="s3">
        <title>Conclusion</title>
        <p>AFA-Recur, a machine-learning-based probability score predicting 1-year risk of recurrent atrial arrhythmia after AF ablation, achieved good predictive performance, significantly better than currently available tools. The calculator, freely available online, allows patient-specific predictions, favouring tailored therapeutic approaches for the individual patient.</p>
      </sec>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="anchor" id="euac145_ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="euac145ga1" position="float"/>
        </fig>
      </p>
    </abstract>
    <kwd-group>
      <kwd>Atrial fibrillation</kwd>
      <kwd>Transcatheter ablation</kwd>
      <kwd>Recurrence</kwd>
      <kwd>Predictors</kwd>
      <kwd>Machine learning</kwd>
    </kwd-group>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Abbott Vascular Int</institution>
            <institution-id institution-id-type="doi">10.13039/100011949</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Amgen Cardiovascular</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>AstraZeneca</institution>
            <institution-id institution-id-type="doi">10.13039/100004325</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Bayer AG</institution>
            <institution-id institution-id-type="doi">10.13039/100004326</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Boehringer Ingelheim</institution>
            <institution-id institution-id-type="doi">10.13039/100001003</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>The Bristol Myers Squibb and Pfizer Alliance</institution>
            <institution-id institution-id-type="doi">10.13039/100002491</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Daiichi Sankyo Europe GmbH</institution>
            <institution-id institution-id-type="doi">10.13039/501100022274</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company</institution>
            <institution-id institution-id-type="doi">10.13039/501100002336</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Gedeon Richter Plc</institution>
            <institution-id institution-id-type="doi">10.13039/501100003358</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Menarini Int. Op</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>MSD-Merck &amp; Co</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Novartis Pharma</institution>
            <institution-id institution-id-type="doi">10.13039/100008792</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>ResMed</institution>
            <institution-id institution-id-type="doi">10.13039/100003305</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Sanofi</institution>
            <institution-id institution-id-type="doi">10.13039/100004339</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Servier</institution>
            <institution-id institution-id-type="doi">10.13039/501100011725</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Vifor</institution>
            <institution-id institution-id-type="doi">10.13039/501100006484</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="9"/>
    </counts>
  </article-meta>
</front>
<body>
  <boxed-text id="euac145-box1" position="anchor">
    <caption>
      <title>What’s new?</title>
    </caption>
    <list list-type="bullet">
      <list-item>
        <p>Supervised machine-learning (ML) algorithms based on pre-procedural, easily accessible, clinical variables from the ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry were used to derive a scoring system to predict the probability of 1-year arrhythmic recurrence after atrial fibrillation catheter ablation.</p>
      </list-item>
      <list-item>
        <p>The best model (random forest) showed good discriminative performance on the testing cohort (area under the curve of 19-variable version: AUC 0.721, 95% confidence interval 0.680–0.764).</p>
      </list-item>
      <list-item>
        <p>The final calibrated model was implemented in a web calculator, freely available online, allowing patient-specific predictions and tailored therapeutic decisions.</p>
      </list-item>
    </list>
  </boxed-text>
  <sec sec-type="intro" id="euac145-s0">
    <title>Introduction</title>
    <p>Atrial fibrillation (AF) is the most common arrhythmia encountered in daily clinical practice, with a currently estimated prevalence in the adult population ranging from 2 to 4%. Atrial fibrillation–associated mortality and morbidity burden is expected to rise in the forthcoming years, as recent epidemiological projections foresee a doubling in prevalence by 2050.<sup><xref rid="euac145-B1" ref-type="bibr">1</xref></sup></p>
    <p>A rhythm-control approach is recommended for symptoms and quality of life<sup><xref rid="euac145-B1" ref-type="bibr">1</xref></sup> improvement, and, as recently documented in the EAST-AFNET 4 trial,<sup><xref rid="euac145-B2" ref-type="bibr">2</xref></sup> it may also achieve a reduction in adverse cardiovascular outcomes, at least in case the arrhythmia is present since &lt;12 months. In this respect, catheter ablation is a well-established option, achieving, compared with antiarrhythmic drugs, superior efficacy in maintaining sinus rhythm,<sup><xref rid="euac145-B3" ref-type="bibr">3</xref></sup> also as first-line option.<sup><xref rid="euac145-B4" ref-type="bibr">4</xref></sup></p>
    <p>However, recurrent AF after catheter ablation remains relatively common and multiple procedures are often required.<sup><xref rid="euac145-B5" ref-type="bibr">5</xref>,<xref rid="euac145-B6" ref-type="bibr">6</xref></sup> Freedom from recurrent AF improves the benefit deriving from AF catheter ablation in terms of symptom relief and possibly also of serious adverse events, given the known association of sinus rhythm maintenance with survival.<sup><xref rid="euac145-B7" ref-type="bibr">7</xref></sup> The need of better patient selection is, therefore, mandatory. Different scoring systems have been proposed to predict recurrent AF after catheter ablation,<sup><xref rid="euac145-B8" ref-type="bibr">8</xref></sup> however, discriminatory abilities of the models are largely suboptimal and most studies did not perform calibration.</p>
    <p>The machine-learning (ML) field is steadily growing and several examples exist of ML-derived scores outperforming traditional risk scores in predicting cardiovascular outcomes.<sup><xref rid="euac145-B9" ref-type="bibr">9</xref>,<xref rid="euac145-B10" ref-type="bibr">10</xref></sup> Aim of the present study is to derive from the prospective, multicentre, multinational European Society of Cardiology (ESC)-EHRA Atrial Fibrillation Ablation Long-Term Registry (AFA-LT), an ML algorithm based on pre-procedural, easily accessible clinical variables, to predict the risk of 1-year recurrence of AF after catheter ablation, as part of a structured management of AF in accordance with recently published AF guidelines.<sup><xref rid="euac145-B1" ref-type="bibr">1</xref></sup></p>
  </sec>
  <sec sec-type="methods" id="euac145-s1">
    <title>Methods</title>
    <sec id="euac145-s1.1">
      <title>Atrial Fibrillation Ablation Long-Term Registry</title>
      <p>The ESC-EHRA AFA-LT is a prospective, multicentre, observational registry of consecutive patients undergoing an AF ablation procedure at 104 centres in 27 countries within the ESC. Participating centres enrolled consecutive patients scheduled for AF ablation between April 2012 and April 2015, following them up for 1 year. Atrial fibrillation was defined as paroxysmal or persistent according to 2010 ESC Guidelines definition.<sup><xref rid="euac145-B11" ref-type="bibr">11</xref></sup> All patients gave written informed consent before study enrolment. Further details regarding the registry may be found in the original publication.<sup><xref rid="euac145-B12" ref-type="bibr">12</xref></sup></p>
    </sec>
    <sec id="euac145-s1.2">
      <title>Outcome assessment</title>
      <p>The investigated outcome was 1-year recurrence, defined as an electrocardiographically documented episode of AF or atrial flutter/tachycardia lasting at least 30 s after a 3-month blanking period from the ablation procedure. As detailed in the original AFA-LT registry publication, 1-year (median 12.4 months, interquartile range 11.9–13.4 months) follow-up evaluation was performed by an in-person clinical visit in 52.8%, a telephone contact in 44.2% and a contact with the patient’s general practitioner in 3.0% of the cases, respectively. During the registry period, strategies for arrhythmia recurrence detection included periodical clinical visits with electrocardiogram (EKG; 78.4%) and 24-h Holter monitoring (64.5%), according to caring physician’s discretion. Trans-telephonic monitoring and implanted monitoring systems were used in 3.4% of the cases, respectively. Overall, at least one EKG was performed in 86% of the patients and 82% had at least one physical evaluation during the 12-month follow up.</p>
    </sec>
    <sec id="euac145-s1.3">
      <title>Study inclusion criteria</title>
      <p>Patients from the ESC-EHRA AFA-LT registry were included in the present study provided that: (i) ablation was performed; (ii) AF type was explicitly specified (paroxysmal or persistent); (iii) 1-year follow-up data regarding arrhythmic recurrences were available.</p>
    </sec>
    <sec id="euac145-s1.4">
      <title>Potential predictors and data pre processing</title>
      <p>The following pre-procedural, easily available, covariates (based on personal history, clinical data, and echocardiographic assessment) were considered as potential candidate variables for the ML models training: age, gender, body mass index (BMI), estimated glomerular filtration rate (CKD-EPI formula were used), smoker status (active, former, never), hypertension, diabetes, dyslipidaemia, history of heart failure, coronary artery disease, structural heart disease (valvular heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy), previous stroke/transient ischemic attack, presence of cardiac rhythm device (either pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy), hyperthyroidism, peripheral artery disease, chronic obstructive pulmonary disease, obstructive sleep apnoea, CHA2DS2-VASc score, AF type (paroxysmal or persistent), history of atrial flutter, previous failed antiarrhythmic therapy, pre-procedural sinus rhythm, abnormal EKG (one or more of the following: atrioventricular block, bundle branch block, Q waves, ST-T abnormalities, and corrected QT &gt; 460 ms), type of procedure (first ablation or re-do procedure), left ventricular ejection fraction (LVEF; %), left atrial (LA) anteroposterior diameter (mm), left ventricular end-diastolic volume (LVEDV; mL). Categorical variables are presented as numbers and percentages, while continuous variables as mean and standard deviation. Missing predictors were imputed using a <italic toggle="yes">k</italic>-nearest neighbour imputation (kNN) technique, with <italic toggle="yes">k</italic> = 5.</p>
    </sec>
    <sec id="euac145-s1.5">
      <title>Score derivation and validation</title>
      <p>The original dataset was randomly split into a training (80%) and testing (20%) cohort. As a preliminary step, a standard backward stepwise logistic regression model was fitted on the training cohort and run on the testing cohort with poor outcome (see <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Figure S1</xref></italic>). Therefore, four different supervised ML classifiers were fitted on the training cohort: decision tree (DT), random forest (RF), AdaBoost (ADA), and kNN. Model hyperparameters were optimized using 10-fold cross validation, fitting the final model with the set of tuning parameters which maximized the mean area under the curve (AUC) across the cross-validation samples. Discrimination of the four tuned models, in terms of AUC, was evaluated in the testing cohort. The model with the best AUC in the testing cohort was chosen as the model of interest, while other models were discarded. Variable importance was then computed for the chosen ML classifier using a filter-based approach. The change in AUC in the testing cohort was then evaluated progressively reducing the number of predictors in the chosen ML model, according to the previously computed variable importance ranking. In order to ensure proper discrimination, while at the same time, limiting model complexity in terms of number of predictors, the model with the best trade-off between discrimination (AUC) and complexity (number of predictors) was selected. The discriminatory ability of the final model in the testing cohort was then compared against the most known score, the APPLE score.<sup><xref rid="euac145-B13" ref-type="bibr">13</xref></sup> Finally, model calibration was assessed on the testing cohort using reliability diagram and Hosmer–Lemeshow test. Platt scaling was performed to re-calibrate model predictions. Frequency distribution of the predicted re-calibrated probabilities and quintile analysis were also computed. The first two quintiles were considered ‘low’, the third and the fourth quintile ‘intermediate’, while the last quintile ‘high’ risk groups in terms of recurrence probability. The final calibrated ML model was used to implement a web-risk calculator.</p>
      <p>All analyses were performed independently at our centre using R software version 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria). In particular, <italic toggle="yes">caret</italic> package (<ext-link xlink:href="https://cran.r-project.org/web/packages/caret/caret.pdf" ext-link-type="uri">https://cran.r-project.org/web/packages/caret/caret.pdf</ext-link>) was used to perform model training and hyperparameter optimization, while <italic toggle="yes">shiny</italic> package (<ext-link xlink:href="https://shiny.rstudio.com/" ext-link-type="uri">https://shiny.rstudio.com/</ext-link>) was used to build the web calculator. A <italic toggle="yes">P</italic>-value &lt;0.05 was considered statistically significant.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="euac145-s2">
    <title>Results</title>
    <p>Overall, 3128 patients from the ESC-EHRA AFA-LT registry satisfied the inclusion criteria and were analysed. <italic toggle="yes">Table <xref rid="euac145-T1" ref-type="table">1</xref></italic> reports main clinical characteristics. Mean age was 58 ± 10 years, and 68.7% were males. Mean CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 1.58 ± 1.32 and 20.6% had history of heart failure. Atrial fibrillation was persistent in 31.9% of the patients. The majority of the ablation procedures were performed with radiofrequency as energy source (83%).</p>
    <table-wrap position="float" id="euac145-T1">
      <label>Table 1</label>
      <caption>
        <p>Baseline clinical variables, stratified by AF recurrence during 1-year follow up</p>
      </caption>
      <table frame="hsides" rules="groups">
        <colgroup span="1">
          <col valign="top" align="left" span="1"/>
          <col valign="top" align="left" span="1"/>
          <col valign="top" align="left" span="1"/>
          <col valign="top" align="left" span="1"/>
          <col valign="top" align="center" span="1"/>
        </colgroup>
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Variables</th>
            <th align="center" rowspan="1" colspan="1">Total (<italic toggle="yes">n</italic> = 3128)</th>
            <th align="center" colspan="3" rowspan="1">Arrhythmic recurrence</th>
          </tr>
          <tr>
            <th rowspan="1" colspan="1"/>
            <th rowspan="1" colspan="1"/>
            <th align="center" rowspan="1" colspan="1">No (<italic toggle="yes">n</italic> = 2331)</th>
            <th align="center" rowspan="1" colspan="1">Yes (<italic toggle="yes">n</italic> = 797)</th>
            <th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">Age (years)</td>
            <td rowspan="1" colspan="1">58.09 (10.28)</td>
            <td rowspan="1" colspan="1">57.99 (10.27)</td>
            <td rowspan="1" colspan="1">58.38 (10.30)</td>
            <td rowspan="1" colspan="1">0.361</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Male gender (%)</td>
            <td rowspan="1" colspan="1">2148 (68.7)</td>
            <td rowspan="1" colspan="1">1604 (68.8)</td>
            <td rowspan="1" colspan="1">544 (68.3)</td>
            <td rowspan="1" colspan="1">0.804</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td>
            <td rowspan="1" colspan="1">28.40 (4.46)</td>
            <td rowspan="1" colspan="1">28.29 (4.45)</td>
            <td rowspan="1" colspan="1">28.74 (4.45)</td>
            <td rowspan="1" colspan="1">0.017</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">eGFR CKDEPI (mL/min/1.73 m<sup>2</sup>)</td>
            <td rowspan="1" colspan="1">80.80 (18.47)</td>
            <td rowspan="1" colspan="1">81.62 (18.30)</td>
            <td rowspan="1" colspan="1">78.47 (18.77)</td>
            <td rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Heart failure (%)</td>
            <td rowspan="1" colspan="1">431 (20.6)</td>
            <td rowspan="1" colspan="1">298 (19.5)</td>
            <td rowspan="1" colspan="1">133 (23.6)</td>
            <td rowspan="1" colspan="1">0.046</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">CAD (%)</td>
            <td rowspan="1" colspan="1">367 (17.9)</td>
            <td rowspan="1" colspan="1">264 (17.6)</td>
            <td rowspan="1" colspan="1">103 (18.4)</td>
            <td rowspan="1" colspan="1">0.730</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Structural heart disease (%)</td>
            <td rowspan="1" colspan="1">535 (25.5)</td>
            <td rowspan="1" colspan="1">379 (24.8)</td>
            <td rowspan="1" colspan="1">156 (27.5)</td>
            <td rowspan="1" colspan="1">0.230</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Stroke/TIA (%)</td>
            <td rowspan="1" colspan="1">96 (3.1)</td>
            <td rowspan="1" colspan="1">68 (2.9)</td>
            <td rowspan="1" colspan="1">28 (3.5)</td>
            <td rowspan="1" colspan="1">0.476</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Device carrier (%)</td>
            <td rowspan="1" colspan="1">138 (4.4)</td>
            <td rowspan="1" colspan="1">87 (3.7)</td>
            <td rowspan="1" colspan="1">51 (6.4)</td>
            <td rowspan="1" colspan="1">0.002</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Smoker status (%)</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">0.066</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">ȃFormer (≥1 month)</td>
            <td rowspan="1" colspan="1">588 (19.7)</td>
            <td rowspan="1" colspan="1">417 (18.8)</td>
            <td rowspan="1" colspan="1">171 (22.4)</td>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">ȃNo</td>
            <td rowspan="1" colspan="1">2082 (69.9)</td>
            <td rowspan="1" colspan="1">1573 (71.0)</td>
            <td rowspan="1" colspan="1">509 (66.7)</td>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">ȃYes</td>
            <td rowspan="1" colspan="1">309 (10.4)</td>
            <td rowspan="1" colspan="1">226 (10.2)</td>
            <td rowspan="1" colspan="1">83 (10.9)</td>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Diabetes (%)</td>
            <td rowspan="1" colspan="1">301 (9.7)</td>
            <td rowspan="1" colspan="1">220 (9.5)</td>
            <td rowspan="1" colspan="1">81 (10.2)</td>
            <td rowspan="1" colspan="1">0.599</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Hypertension (%)</td>
            <td rowspan="1" colspan="1">1680 (53.9)</td>
            <td rowspan="1" colspan="1">1221 (52.7)</td>
            <td rowspan="1" colspan="1">459 (57.6)</td>
            <td rowspan="1" colspan="1">0.019</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Dyslipidaemia (%)</td>
            <td rowspan="1" colspan="1">988 (32.2)</td>
            <td rowspan="1" colspan="1">739 (32.4)</td>
            <td rowspan="1" colspan="1">249 (31.8)</td>
            <td rowspan="1" colspan="1">0.809</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Hyperthyroidism (%)</td>
            <td rowspan="1" colspan="1">72 (2.3)</td>
            <td rowspan="1" colspan="1">45 (2.0)</td>
            <td rowspan="1" colspan="1">27 (3.5)</td>
            <td rowspan="1" colspan="1">0.026</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">PAD (%)</td>
            <td rowspan="1" colspan="1">55 (1.8)</td>
            <td rowspan="1" colspan="1">42 (1.8)</td>
            <td rowspan="1" colspan="1">13 (1.6)</td>
            <td rowspan="1" colspan="1">0.751</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">COPD (%)</td>
            <td rowspan="1" colspan="1">69 (2.3)</td>
            <td rowspan="1" colspan="1">49 (2.2)</td>
            <td rowspan="1" colspan="1">20 (2.5)</td>
            <td rowspan="1" colspan="1">0.616</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Obstructive sleep apnoea (%)</td>
            <td rowspan="1" colspan="1">105 (3.6)</td>
            <td rowspan="1" colspan="1">80 (3.7)</td>
            <td rowspan="1" colspan="1">25 (3.4)</td>
            <td rowspan="1" colspan="1">0.762</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td>
            <td rowspan="1" colspan="1">1.58 (1.32)</td>
            <td rowspan="1" colspan="1">1.55 (1.32)</td>
            <td rowspan="1" colspan="1">1.66 (1.33)</td>
            <td rowspan="1" colspan="1">0.043</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">AF type (%)</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">0.005</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">ȃParoxysmal AF</td>
            <td rowspan="1" colspan="1">2130 (68.1)</td>
            <td rowspan="1" colspan="1">1620 (69.5)</td>
            <td rowspan="1" colspan="1">510 (64.0)</td>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">ȃPersistent AF</td>
            <td rowspan="1" colspan="1">998 (31.9)</td>
            <td rowspan="1" colspan="1">711 (30.5)</td>
            <td rowspan="1" colspan="1">287 (36.0)</td>
            <td rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">AFL (%)</td>
            <td rowspan="1" colspan="1">724 (24.1)</td>
            <td rowspan="1" colspan="1">529 (23.6)</td>
            <td rowspan="1" colspan="1">195 (25.7)</td>
            <td rowspan="1" colspan="1">0.264</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Previous failed antiarrhythmic drugs (%)</td>
            <td rowspan="1" colspan="1">2782 (89.7)</td>
            <td rowspan="1" colspan="1">2064 (89.3)</td>
            <td rowspan="1" colspan="1">718 (90.8)</td>
            <td rowspan="1" colspan="1">0.273</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Baseline LVEF (%)</td>
            <td rowspan="1" colspan="1">59.81 (8.54)</td>
            <td rowspan="1" colspan="1">60.01 (8.49)</td>
            <td rowspan="1" colspan="1">59.20 (8.65)</td>
            <td rowspan="1" colspan="1">0.045</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Baseline LVEDV (mL)</td>
            <td rowspan="1" colspan="1">112.47 (30.62)</td>
            <td rowspan="1" colspan="1">112.84 (30.17)</td>
            <td rowspan="1" colspan="1">111.57 (31.74)</td>
            <td rowspan="1" colspan="1">0.543</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Baseline LA diameter (mm)</td>
            <td rowspan="1" colspan="1">42.63 (6.67)</td>
            <td rowspan="1" colspan="1">42.22 (6.64)</td>
            <td rowspan="1" colspan="1">43.81 (6.61)</td>
            <td rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Baseline sinus rhythm (%)</td>
            <td rowspan="1" colspan="1">1968 (62.9)</td>
            <td rowspan="1" colspan="1">1514 (65.0)</td>
            <td rowspan="1" colspan="1">454 (57.0)</td>
            <td rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Abnormal ECG (%)</td>
            <td rowspan="1" colspan="1">1885 (60.3)</td>
            <td rowspan="1" colspan="1">1362 (58.4)</td>
            <td rowspan="1" colspan="1">523 (65.6)</td>
            <td rowspan="1" colspan="1">&lt;0.001</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Re-do procedure (%)</td>
            <td rowspan="1" colspan="1">674 (21.5)</td>
            <td rowspan="1" colspan="1">490 (21.0)</td>
            <td rowspan="1" colspan="1">184 (23.1)</td>
            <td rowspan="1" colspan="1">0.240</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="euac145-tblfn1">
          <p>AF, atrial fibrillation; AFL, atrial flutter; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; LA, left atrium; LVEDV, left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; PAD, peripheral artery disease; TIA, transient ischaemic attack.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <p>During 1-year follow up, 797 patients (25.8%) experienced at least one arrhythmic recurrence (23.9% within paroxysmal AF patients). Baseline clinical variables, stratified by the presence of a recurrence during follow up, are reported in <italic toggle="yes">Table <xref rid="euac145-T1" ref-type="table">1</xref></italic>. Patients with arrhythmic recurrence more likely had persistent AF, history of heart failure, impaired renal function, and presented higher CHA<sub>2</sub>DS<sub>2</sub>-VASc score and BMI when compared with patients without recurrences. Additionally, those with recurrence showed greater LA anteroposterior diameter and lower LVEF than those without.</p>
    <p>Four different supervised ML classifiers (DT, RF, ADA, and kNN) were fitted and tuned on the training cohort (full details of the 10-fold cross validation on the training cohort for the optimally tuned models can be found in <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S1</xref></italic>; AUC 0.722, interquartile range 0.691–0.739 for the RF model). Receiver operating characteristics with the corresponding AUC on the testing cohort for the different models are reported in <italic toggle="yes">Figure <xref rid="euac145-F1" ref-type="fig">1</xref></italic>, with the RF model showing the best discriminative performance [AUC 0.718, 95% confidence interval (CI) 0.674–0.761] and thus chosen as the model of interest. <italic toggle="yes">Figure <xref rid="euac145-F2" ref-type="fig">2A</xref></italic> reports variable ranking in the RF model. In order to ensure proper discrimination, while limiting model complexity, the change in AUC in the testing cohort was evaluated progressively reducing the number of predictors (starting by eliminating those with the lowest ranking). Simplified RF models were fitted (<italic toggle="yes">K</italic> features, with <italic toggle="yes">K</italic> ranging from 1 to 27), and the resulting AUC in the testing cohort was then plotted against the number of variables included in the model (<italic toggle="yes">Figure <xref rid="euac145-F2" ref-type="fig">2B</xref></italic>). Given a plateau in the model discrimination was reached after 19 variables, a 19-variable RF model was chosen as the final ML classifier (<italic toggle="yes">Table <xref rid="euac145-T2" ref-type="table">2</xref></italic>).</p>
    <fig position="float" id="euac145-F1" fig-type="figure">
      <label>Figure 1</label>
      <caption>
        <p>Receiver operator curve curves and corresponding AUC of the four evaluated machine-learning classifiers. AUC, area under the receiver operator curve.</p>
      </caption>
      <graphic xlink:href="euac145f1" position="float"/>
    </fig>
    <fig position="float" id="euac145-F2" fig-type="figure">
      <label>Figure 2</label>
      <caption>
        <p>Random forest model selection. (<italic toggle="yes">A</italic>) Variable ranking for the 27 original predictors; (<italic toggle="yes">B</italic>) the number of included variables strengthens the model AUC reaching a plateau at 19; (<italic toggle="yes">C</italic>) ROC curve and corresponding AUC of the final 19-variable random forest model. AAD, antiarrhythmic drug; AFL, atrial flutter; AUC, area under the receiver operator curve; AFL, atrial flutter; BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; LA, left atrium; LVEDV, left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; PAD, peripheral artery disease; RF: random forest; ROC: receiver operator curve.</p>
      </caption>
      <graphic xlink:href="euac145f2" position="float"/>
    </fig>
    <table-wrap position="float" id="euac145-T2">
      <label>Table 2</label>
      <caption>
        <p>Variables included in the final random forest model</p>
      </caption>
      <table frame="hsides" rules="groups">
        <colgroup span="1">
          <col valign="top" align="left" span="1"/>
        </colgroup>
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Included variables</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">
              <list list-type="bullet">
                <list-item>
                  <p>LVEDV</p>
                </list-item>
                <list-item>
                  <p>Estimated glomerular filtration rate (CKD-EPI formula)</p>
                </list-item>
                <list-item>
                  <p>BMI</p>
                </list-item>
                <list-item>
                  <p>Age</p>
                </list-item>
                <list-item>
                  <p>LA anteroposterior diameter</p>
                </list-item>
                <list-item>
                  <p>LVEF</p>
                </list-item>
                <list-item>
                  <p>CHAD2DS2-VASc score</p>
                </list-item>
                <list-item>
                  <p>Dyslipidaemia</p>
                </list-item>
                <list-item>
                  <p>AFL</p>
                </list-item>
                <list-item>
                  <p>Type of procedure (first procedure or re-do)</p>
                </list-item>
                <list-item>
                  <p>Atrial fibrillation type (paroxysmal or persistent)</p>
                </list-item>
                <list-item>
                  <p>Structural heart disease</p>
                </list-item>
                <list-item>
                  <p>Hypertension</p>
                </list-item>
                <list-item>
                  <p>Baseline sinus rhythm</p>
                </list-item>
                <list-item>
                  <p>Gender</p>
                </list-item>
                <list-item>
                  <p>Abnormal ECG</p>
                </list-item>
                <list-item>
                  <p>Heart failure</p>
                </list-item>
                <list-item>
                  <p>CAD</p>
                </list-item>
                <list-item>
                  <p>Smoker</p>
                </list-item>
              </list>
            </td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="euac145-tblfn2">
          <p>AFL, atrial flutter; BMI, body mass index; CAD, coronary artery disease; LA, left atrium; LVEDV, left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <p>The AUC of the final model on the testing cohort was 0.721 (95% CI 0.680–0.764), outperforming the APPLE score in predicting outcomes in the testing cohort (AUC 0.557, 95% CI 0.506–0.607; see <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Figure S2</xref></italic>).</p>
    <p>Eventually, given the uncalibrated predictions of the model (Hosmer–Lemeshow test <italic toggle="yes">P</italic> = 0.005), due to over-forecasting in the left lower quadrant of the reliability plot (<italic toggle="yes">Figure <xref rid="euac145-F3" ref-type="fig">3A</xref></italic>), calibration was effectively performed by Platt scaling (<italic toggle="yes">Figure <xref rid="euac145-F3" ref-type="fig">3B</xref></italic>; Hosmer–Lemeshow test <italic toggle="yes">P</italic> = 0.063). Frequency distribution of predicted probabilities after re-calibration is reported in <italic toggle="yes">Figure <xref rid="euac145-F4" ref-type="fig">4A</xref></italic>. Quintile analysis (<italic toggle="yes">Figure <xref rid="euac145-F4" ref-type="fig">4B</xref></italic>) defines three levels of progressively higher risk of recurrence: the first two quintiles comprise the ‘low’ (predicted probability range: 0.04–0.19), the third and the fourth quintiles the ‘intermediate’ (predicted probability range: 0.19–0.38), while the remaining upper quintile indicates the ‘higher risk group’ (predicted probability range: 0.38–0.76).</p>
    <fig position="float" id="euac145-F3" fig-type="figure">
      <label>Figure 3</label>
      <caption>
        <p>Random forest model calibration on the testing cohort. (<italic toggle="yes">A</italic>) Calibration plot before Platt scaling, showing uncalibrated predictions. (<italic toggle="yes">B</italic>) Calibration plot after Platt scaling, yielding improved calibration.</p>
      </caption>
      <graphic xlink:href="euac145f3" position="float"/>
    </fig>
    <fig position="float" id="euac145-F4" fig-type="figure">
      <label>Figure 4</label>
      <caption>
        <p>Predicted probability distribution and quantile analysis on the testing cohort. (<italic toggle="yes">A</italic>) Frequency distribution of the predicted probabilities of AF recurrence (after re-calibration with Platt scaling). (<italic toggle="yes">B</italic>) Quintile analysis of the predicted probability distribution; the first two quintiles are considered ‘low risk’ (green), the third and the fourth ‘intermediate-risk’ (yellow), while the last quintile represent ‘high risk’ (red) for AF recurrence after catheter ablation.</p>
      </caption>
      <graphic xlink:href="euac145f4" position="float"/>
    </fig>
    <p>The final re-calibrated RF model was ultimately implemented in a web calculator, freely available at <ext-link xlink:href="http://afarec.hpc4ai.unito.it/" ext-link-type="uri">http://afarec.hpc4ai.unito.it/</ext-link>, allowing the user to input predictor values to obtain the probability output of 1-year AF recurrence for a specific patient, as well as its associated risk class (<italic toggle="yes">Figure <xref rid="euac145-F5" ref-type="fig">5</xref></italic>).</p>
    <fig position="float" id="euac145-F5" fig-type="figure">
      <label>Figure 5</label>
      <caption>
        <p>Screenshots of the freely available web calculator (<ext-link xlink:href="http://afarec.hpc4ai.unito.it/" ext-link-type="uri">http://afarec.hpc4ai.unito.it/</ext-link>), which allows the user to input predictor values to obtain a probability output of 1-year AF recurrence, as well as the associated risk class, for a specific patient.</p>
      </caption>
      <graphic xlink:href="euac145f5" position="float"/>
    </fig>
  </sec>
  <sec sec-type="discussion" id="euac145-s3">
    <title>Discussion</title>
    <p>Catheter ablation has become a safe and well-established option in rhythm-control management of symptomatic AF patients.<sup><xref rid="euac145-B1" ref-type="bibr">1</xref></sup> Although the recent Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial did not reach formal statistical evidence in composite primary outcome, it revealed that catheter ablation reduces death or cardiovascular hospitalization (secondary endpoint<sup><xref rid="euac145-B3" ref-type="bibr">3</xref></sup>). In addition, clinical trials performed in patients with concomitant heart failure,<sup><xref rid="euac145-B14" ref-type="bibr">14</xref></sup> and observational real-world evidences,<sup><xref rid="euac145-B15" ref-type="bibr">15</xref></sup> suggest catheter ablation may be superior to medical therapy in reducing cardiovascular outcomes.</p>
    <p>Efficacy of AF catheter ablation, however, remains an issue,<sup><xref rid="euac145-B5" ref-type="bibr">5</xref>,<xref rid="euac145-B6" ref-type="bibr">6</xref></sup> with recurrence rates after a single procedure ranging between 20 and 45%.<sup><xref rid="euac145-B16" ref-type="bibr">16</xref>,<xref rid="euac145-B17" ref-type="bibr">17</xref></sup> Part of the issue relates to inadequate durability of the ablation lesions, which may be solved by technological improvements. The remaining portion reflects, instead, the presence of complex myocardial substrate, the result of multiple clinical risk factors, and comorbidities. To avoid futile interventions, proper patient selection is therefore fundamental. Known risk factors associated with arrhythmia recurrence include persistent AF, enlarged left atrium, and presence of underlying structural cardiopathy.<sup><xref rid="euac145-B18" ref-type="bibr">18</xref>,<xref rid="euac145-B19" ref-type="bibr">19</xref></sup> In this regard, several prognostic models combining different predictors have been proposed. However, a recent meta-analysis<sup><xref rid="euac145-B8" ref-type="bibr">8</xref></sup> evaluating 13 prognostic models showed that the discriminatory ability of the models was suboptimal, with no model proving consistently good performance in predicting rhythm outcome. In addition, none of the thirteen models underwent internal validation, translating into an overly optimistic prediction of performance of the model when used in unknown populations. Furthermore, only two out of 13 models assessed calibration, lacking, in the majority of cases, an important step in model optimization.</p>
    <p>In the present study, we derived and tested the first ML-based probability score of the risk of recurrent arrhythmic events in patients undergoing AF catheter ablation (AFA-Recur), based on the widest available, prospective, multicentre, multinational, observational registry of the ESC (ESC-EHRA AFA-LT). Machine learning is a rapidly evolving field, with increasing use in cardiovascular medicine.<sup><xref rid="euac145-B20" ref-type="bibr">20</xref></sup> It broadly refers to analytical algorithms that iteratively learn from data, discovering hidden, but potentially relevant, associations without being explicitly programmed where to search. In fact, the main advantage of ML-based approach is that it takes into account multiple, complex, non-linear interactions between the various characteristics and comorbidities that constitute the full portrait of each patient, without the need of directly specifying variable interaction terms such as in traditional statistical approaches (e.g. logistic regression). Recent studies have shown that ML-based cardiovascular predictive modelling outperforms traditional risk scores,<sup><xref rid="euac145-B9" ref-type="bibr">9</xref>,<xref rid="euac145-B21" ref-type="bibr">21</xref></sup> and have been assessed in several clinical scenarios.<sup><xref rid="euac145-B22" ref-type="bibr">22</xref></sup> Our work strengthens this consideration; in fact, the present ML-based probability risk score shows good performance in predicting 1-year arrhythmic recurrence after catheter ablation, outperforming the most widely used existing risk score, the APPLE score.<sup><xref rid="euac145-B13" ref-type="bibr">13</xref></sup></p>
    <p>An additional novelty of the present score is that it is derived from a heterogeneous population, originating from 104 centres in 27 countries within the ESC. Differently from previous risk scores developed in highly selected populations, the multicentre, multinational nature of the ESC-EHRA AFA-LT registry grants the opportunity to capture the heterogeneity that exists between different centres and countries in terms of patient selection and procedural features, highly representative of a real-life scenario. Furthermore, the prospective nature of ESC-EHRA AFA-LT registry ensures that patients are not selected based on availability of predictors or outcome data.</p>
    <sec id="euac145-s3.1">
      <title>Limitations</title>
      <p>Some limitations of the present study need to be addressed. First, since only a limited quote of patients were implanted with loop recorders after the procedure, brief, asymptomatic arrhythmia recurrences may have been missed in outcome adjudication. However, previous literature suggests that only a small percentage of patients clinically considered arrhythmia-free after catheter ablation may meet ablation failure definition (recurrent arrhythmia lasting &gt;30 s) using long-term electrocardiographic monitoring.<sup><xref rid="euac145-B23" ref-type="bibr">23</xref></sup> Additionally, being symptom control the main goal for AF ablation, brief asymptomatic arrhythmias may not represent a clear procedural failure.</p>
      <p>Second, ESC-EHRA AFA-LT registry defined AF as paroxysmal or persistent according to 2010 ESC Guidelines definition,<sup><xref rid="euac145-B11" ref-type="bibr">11</xref></sup> and definitions have changed in the subsequent guidelines, leading to a marked shift from persistent to paroxysmal AF. It should be noted, however, that a recent report hints that the original definition might provide a better separator to predict rhythm outcome after AF ablation.<sup><xref rid="euac145-B24" ref-type="bibr">24</xref></sup></p>
      <p>Finally, given the minority of patients undergoing cryoballoon ablation in this population (16%), the present score might mainly apply to patients undergoing radiofrequency ablation. In fact, although success rate by cryoballoon is equivalent to radiofrequency ablation,<sup><xref rid="euac145-B25" ref-type="bibr">25</xref></sup> recurrence predictors between the two approaches might differ. The preponderance of patients undergoing radiofrequency ablation precluded subgroup analysis to potentially identify differential predictors of recurrence between different devices and energy sources.</p>
    </sec>
  </sec>
  <sec id="euac145-s4">
    <title>Conclusions</title>
    <p>Based on the widest available, prospective, multicentre, multination observational registry of AF patients undergoing catheter ablation (ESC-EHRA AFA-LT registry), we derived and tested an ML-based probability score evaluating 1-year risk of recurrent arrhythmic events after ablation (AFA-Recur).</p>
    <p>The freely available online calculator (<ext-link xlink:href="http://afarec.hpc4ai.unito.it/" ext-link-type="uri">http://afarec.hpc4ai.unito.it/</ext-link>) offers end users the possibility to predict, by inserting easily derived pre-procedural clinical variables, the patient-specific risk of recurrent atrial arrhythmias after ablation. The good discriminative performance achieved by the model enables tailored therapeutic approaches for the individual patient.</p>
  </sec>
  <sec sec-type="supplementary-material" id="euac145-s5">
    <title>Supplementary material</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> is available at <italic toggle="yes">Europace</italic> online.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>euac145_Supplementary_Data</label>
      <media xlink:href="euac145_supplementary_data.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>Data collection was conducted by the EURObservational Research Program (EORP) department (EORP Oversight Committee, Registry Executive Committee, and Steering Committee of the EORP) from the ESC by Elin Folkesson Lefrancq as project officer and Viviane Missiamenou as data manager. Statistical analyses were performed by Cécile Laroche. Overall activities were co-ordinated and supervised by Dr Aldo P. Maggioni (EORP scientific co-ordinator). The names of all investigators are listed in <xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>.</p>
  </ack>
  <sec id="euac145-s6">
    <title>Funding</title>
    <p>Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–21), Amgen (2009–18), AstraZeneca (2014–21), Bayer (2009–18), Boehringer Ingelheim (2009–19), Boston Scientific (2009–12), The Bristol Myers Squibb and Pfizer Alliance (2011–19), Daiichi Sankyo Europe (2011–20), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014–17), Edwards (2016–19), Gedeon Richter Plc. (2014–16), Menarini Group. (2009–12), Merck Sharp and Dohme. (2011–14), Novartis Pharma (2014–20), ResMed (2014–16), Sanofi (2009–11), Servier (2009–21), and Vifor (2019–22).</p>
  </sec>
  <sec sec-type="data-availability" id="euac145-s7">
    <title>Data availability</title>
    <p>The data underlying this article were provided by ESC with permission.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="euac145-B1">
      <label>1</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hindricks</surname><given-names>G</given-names></string-name>, <string-name><surname>Potpara</surname><given-names>T</given-names></string-name>, <string-name><surname>Dagres</surname><given-names>N</given-names></string-name>, <string-name><surname>Arbelo</surname><given-names>E</given-names></string-name>, <string-name><surname>Bax</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Blomström-Lundqvist</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group><article-title>2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC</article-title>. <source>Eur Heart J</source><year>2021</year>;<volume>42</volume>:<fpage>373</fpage>–<lpage>498</lpage>.<pub-id pub-id-type="pmid">32860505</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B2">
      <label>2</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kirchhof</surname><given-names>P</given-names></string-name>, <string-name><surname>Camm</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Goette</surname><given-names>A</given-names></string-name>, <string-name><surname>Brandes</surname><given-names>A</given-names></string-name>, <string-name><surname>Eckardt</surname><given-names>L</given-names></string-name>, <string-name><surname>Elvan</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group><article-title>Early rhythm-control therapy in patients with atrial fibrillation</article-title>. <source>N Engl J Med</source><year>2020</year>;<volume>383</volume>:<fpage>1305</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">32865375</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B3">
      <label>3</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Packer</surname><given-names>DL</given-names></string-name>, <string-name><surname>Mark</surname><given-names>DB</given-names></string-name>, <string-name><surname>Robb</surname><given-names>RA</given-names></string-name>, <string-name><surname>Monahan</surname><given-names>KH</given-names></string-name>, <string-name><surname>Bahnson</surname><given-names>TD</given-names></string-name>, <string-name><surname>Poole</surname><given-names>JE</given-names></string-name><etal>et al</etal></person-group><article-title>Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial</article-title>. <source>JAMA</source><year>2019</year>;<volume>321</volume>:<fpage>1261</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">30874766</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B4">
      <label>4</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saglietto</surname><given-names>A</given-names></string-name>, <string-name><surname>Gaita</surname><given-names>F</given-names></string-name>, <string-name><surname>De Ponti</surname><given-names>R</given-names></string-name>, <string-name><surname>De Ferrari</surname><given-names>GM</given-names></string-name>, <string-name><surname>Anselmino</surname><given-names>M</given-names></string-name></person-group>. <article-title>Catheter ablation vs. anti-arrhythmic drugs as first-line treatment in symptomatic paroxysmal atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials</article-title>. <source>Front Cardiovasc Med</source><year>2021</year>;<volume>8</volume>:<fpage>664647</fpage>.<pub-id pub-id-type="pmid">34095254</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B5">
      <label>5</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ganesan</surname><given-names>AN</given-names></string-name>, <string-name><surname>Shipp</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Brooks</surname><given-names>AG</given-names></string-name>, <string-name><surname>Kuklik</surname><given-names>P</given-names></string-name>, <string-name><surname>Lau</surname><given-names>DH</given-names></string-name>, <string-name><surname>Lim</surname><given-names>HS</given-names></string-name><etal>et al</etal></person-group><article-title>Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis</article-title>. <source>J Am Heart Assoc</source><year>2013</year>;<volume>2</volume>:<fpage>e004549</fpage>.<pub-id pub-id-type="pmid">23537812</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B6">
      <label>6</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gaita</surname><given-names>F</given-names></string-name>, <string-name><surname>Scaglione</surname><given-names>M</given-names></string-name>, <string-name><surname>Battaglia</surname><given-names>A</given-names></string-name>, <string-name><surname>Matta</surname><given-names>M</given-names></string-name>, <string-name><surname>Gallo</surname><given-names>C</given-names></string-name>, <string-name><surname>Galatà</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group><part-title>Very long-term outcome following transcatheter ablation of atrial fibrillation. are results maintained after 10 years of follow up?</part-title><source>Europace</source><year>2018</year>;<volume>20</volume>:<fpage>443</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">28340043</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B7">
      <label>7</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Epstein</surname><given-names>AE</given-names></string-name></person-group>. <article-title>Relationships between sinus rhythm. Treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study</article-title>. <source>Circulation</source><year>2004</year>;<volume>109</volume>:<fpage>1509</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">15007003</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B8">
      <label>8</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dretzke</surname><given-names>J</given-names></string-name>, <string-name><surname>Chuchu</surname><given-names>N</given-names></string-name>, <string-name><surname>Agarwal</surname><given-names>R</given-names></string-name>, <string-name><surname>Herd</surname><given-names>C</given-names></string-name>, <string-name><surname>Chua</surname><given-names>W</given-names></string-name>, <string-name><surname>Fabritz</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group><article-title>Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models</article-title>. <source>Europace</source><year>2020</year>;<volume>22</volume>:<fpage>748</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">32227238</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B9">
      <label>9</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sánchez-Cabo</surname><given-names>F</given-names></string-name>, <string-name><surname>Rossello</surname><given-names>X</given-names></string-name>, <string-name><surname>Fuster</surname><given-names>V</given-names></string-name>, <string-name><surname>Benito</surname><given-names>F</given-names></string-name>, <string-name><surname>Manzano</surname><given-names>JP</given-names></string-name>, <string-name><surname>Silla</surname><given-names>JC</given-names></string-name><etal>et al</etal></person-group><article-title>Machine learning improves cardiovascular risk definition for young. Asymptomatic individuals</article-title>. <source>J Am Coll Cardiol</source><year>2020</year>;<volume>76</volume>:<fpage>1674</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">33004133</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B10">
      <label>10</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>D’Ascenzo</surname><given-names>F</given-names></string-name>, <string-name><surname>De Filippo</surname><given-names>O</given-names></string-name>, <string-name><surname>Gallone</surname><given-names>G</given-names></string-name>, <string-name><surname>Mittone</surname><given-names>G</given-names></string-name>, <string-name><surname>Deriu</surname><given-names>MA</given-names></string-name>, <string-name><surname>Iannaccone</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group><article-title>Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets</article-title>. <source>Lancet</source><year>2021</year>;<volume>397</volume>:<fpage>199</fpage>–<lpage>207</lpage>.<pub-id pub-id-type="pmid">33453782</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B11">
      <label>11</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Camm</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Kirchhof</surname><given-names>P</given-names></string-name>, <string-name><surname>Lip</surname><given-names>GYH</given-names></string-name>, <string-name><surname>Schotten</surname><given-names>U</given-names></string-name>, <string-name><surname>Savelieva</surname><given-names>I</given-names></string-name>, <string-name><surname>Ernst</surname><given-names>S</given-names></string-name><etal>et al</etal></person-group><article-title>Guidelines for the management of atrial fibrillation</article-title>. <source>Europace</source><year>2010</year>;<volume>12</volume>:<fpage>1360</fpage>–<lpage>420</lpage>.<pub-id pub-id-type="pmid">20876603</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B12">
      <label>12</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arbelo</surname><given-names>E</given-names></string-name>, <string-name><surname>Brugada</surname><given-names>J</given-names></string-name>, <string-name><surname>Blomström-Lundqvist</surname><given-names>C</given-names></string-name>, <string-name><surname>Laroche</surname><given-names>C</given-names></string-name>, <string-name><surname>Kautzner</surname><given-names>J</given-names></string-name>, <string-name><surname>Pokushalov</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group><article-title>Contemporarymanagement of patients undergoing atrial fibrillation ablation: inhospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry</article-title>. <source>Eur Heart J</source><year>2017</year>;<volume>38</volume>:<fpage>1303</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">28104790</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B13">
      <label>13</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kornej</surname><given-names>J</given-names></string-name>, <string-name><surname>Hindricks</surname><given-names>G</given-names></string-name>, <string-name><surname>Shoemaker</surname><given-names>MB</given-names></string-name>, <string-name><surname>Husser</surname><given-names>D</given-names></string-name>, <string-name><surname>Arya</surname><given-names>A</given-names></string-name>, <string-name><surname>Sommer</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group><article-title>The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation</article-title>. <source>Clin Res Cardiol</source><year>2015</year>;<volume>104</volume>:<fpage>871</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">25876528</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B14">
      <label>14</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marrouche</surname><given-names>NF</given-names></string-name>, <string-name><surname>Brachmann</surname><given-names>J</given-names></string-name>, <string-name><surname>Andresen</surname><given-names>D</given-names></string-name>, <string-name><surname>Siebels</surname><given-names>J</given-names></string-name>, <string-name><surname>Boersma</surname><given-names>L</given-names></string-name>, <string-name><surname>Jordaens</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group><article-title>Catheter ablation for atrial fibrillation with heart failure</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>378</volume>:<fpage>417</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">29385358</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B15">
      <label>15</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saglietto</surname><given-names>A</given-names></string-name>, <string-name><surname>De Ponti</surname><given-names>R</given-names></string-name>, <string-name><surname>Di Biase</surname><given-names>L</given-names></string-name>, <string-name><surname>Matta</surname><given-names>M</given-names></string-name>, <string-name><surname>Gaita</surname><given-names>F</given-names></string-name>, <string-name><surname>Romero</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group><article-title>Impact of atrial fibrillation catheter ablation on mortality, stroke, and heart failure hospitalizations: a meta-analysis</article-title>. <source>J Cardiovasc Electrophysiol</source><year>2020</year>;<volume>31</volume>:<fpage>1040</fpage>–<lpage>104</lpage>.<pub-id pub-id-type="pmid">32115777</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B16">
      <label>16</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Darby</surname><given-names>AE</given-names></string-name></person-group>. <article-title>Recurrent atrial fibrillation after catheter ablation: considerations for repeat ablation and strategies to optimize success</article-title>. <source>J Atr Fibrillation</source><year>2016</year>;<volume>9</volume>:<fpage>1427</fpage>.<pub-id pub-id-type="pmid">27909521</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B17">
      <label>17</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sultan</surname><given-names>A</given-names></string-name>, <string-name><surname>Lüker</surname><given-names>J</given-names></string-name>, <string-name><surname>Andresen</surname><given-names>D</given-names></string-name>, <string-name><surname>Kuck</surname><given-names>KH</given-names></string-name>, <string-name><surname>Hoffmann</surname><given-names>E</given-names></string-name>, <string-name><surname>Brachmann</surname><given-names>J</given-names></string-name>, <string-name><surname>Hochadel</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group><article-title>Predictors of atrial fibrillation recurrence after catheter ablation: data from the German ablation registry</article-title>. <source>Sci Rep</source><year>2017</year>;<volume>7</volume>:<fpage>16678</fpage>.<pub-id pub-id-type="pmid">29192223</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B18">
      <label>18</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Balk</surname><given-names>EM</given-names></string-name>, <string-name><surname>Garlitski</surname><given-names>AC</given-names></string-name>, <string-name><surname>Alsheikh-Ali</surname><given-names>AA</given-names></string-name>, <string-name><surname>Terasawa</surname><given-names>T</given-names></string-name>, <string-name><surname>Chung</surname><given-names>M</given-names></string-name>, <string-name><surname>Ip</surname><given-names>S</given-names></string-name></person-group>. <article-title>Predictors of atrial fibrillation recurrence after radiofrequency catheter ablation: a systematic review</article-title>. <source>J Cardiovasc Electrophysiol</source><year>2010</year>:<fpage>1208</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">20487117</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B19">
      <label>19</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>D’Ascenzo</surname><given-names>F</given-names></string-name>, <string-name><surname>Corleto</surname><given-names>A</given-names></string-name>, <string-name><surname>Biondi-Zoccai</surname><given-names>G</given-names></string-name>, <string-name><surname>Anselmino</surname><given-names>M</given-names></string-name>, <string-name><surname>Ferraris</surname><given-names>F</given-names></string-name>, <string-name><surname>di Biase</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group><article-title>Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation? A meta-analysis</article-title>. <source>Int J Cardiol</source><year>2013</year>;<volume>167</volume>:<fpage>1984</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">22626840</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B20">
      <label>20</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shameer</surname><given-names>K</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>KW</given-names></string-name>, <string-name><surname>Glicksberg</surname><given-names>BS</given-names></string-name>, <string-name><surname>Dudley</surname><given-names>JT</given-names></string-name>, <string-name><surname>Sengupta</surname><given-names>PP</given-names></string-name></person-group>. <article-title>Machine learning in cardiovascular medicine: are we there yet? Heart</article-title>. <source>BMJ</source><year>2018</year>;<volume>104</volume>:<fpage>1156</fpage>–<lpage>64</lpage>.</mixed-citation>
    </ref>
    <ref id="euac145-B21">
      <label>21</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vergara</surname><given-names>P</given-names></string-name>, <string-name><surname>Tzou</surname><given-names>WS</given-names></string-name>, <string-name><surname>Tung</surname><given-names>R</given-names></string-name>, <string-name><surname>Brombin</surname><given-names>C</given-names></string-name>, <string-name><surname>Nonis</surname><given-names>A</given-names></string-name>, <string-name><surname>Vaseghi</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group><article-title>Predictive score for identifying survival and recurrence risk profiles in patients undergoing ventricular tachycardia ablation: the I-VT score</article-title>. <source>Circ Arrhythm Electrophysiol</source><year>2018</year>;<volume>11</volume>:<fpage>e006730</fpage>.<pub-id pub-id-type="pmid">30562104</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B22">
      <label>22</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Crea</surname><given-names>F</given-names></string-name></person-group>. <article-title>Prediction of sudden death in the era of personalized medicine</article-title>. <source>Eur Heart J</source><year>2021</year>;<volume>42</volume>:<fpage>1641</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">34009319</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B23">
      <label>23</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Winkle</surname><given-names>RA</given-names></string-name>, <string-name><surname>Mead</surname><given-names>RH</given-names></string-name>, <string-name><surname>Engel</surname><given-names>G</given-names></string-name>, <string-name><surname>Kong</surname><given-names>MH</given-names></string-name>, <string-name><surname>Patrawala</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Atrial arrhythmia burden on long-term monitoring in asymptomatic patients late after atrial fibrillation ablation</article-title>. <source>Am J Cardiol</source><year>2012</year>;<volume>110</volume>:<fpage>840</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">22658502</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B24">
      <label>24</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weinmann</surname><given-names>K</given-names></string-name>, <string-name><surname>Aktolga</surname><given-names>D</given-names></string-name>, <string-name><surname>Pott</surname><given-names>A</given-names></string-name>, <string-name><surname>Bothner</surname><given-names>C</given-names></string-name>, <string-name><surname>Rattka</surname><given-names>M</given-names></string-name>, <string-name><surname>Stephan</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group><article-title>Impact of re-definition of paroxysmal and persistent atrial fibrillation in the 2012 and 2016 European Society of Cardiology Atrial Fibrillation Guidelines on outcomes after pulmonary vein isolation</article-title>. <source>J Interv Card Electrophysiol</source><year>2021</year>;<volume>60</volume>:<fpage>115</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">32124151</pub-id></mixed-citation>
    </ref>
    <ref id="euac145-B25">
      <label>25</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuck</surname><given-names>KH</given-names></string-name>, <string-name><surname>Brugada</surname><given-names>J</given-names></string-name>, <string-name><surname>Fürnkranz</surname><given-names>A</given-names></string-name>, <string-name><surname>Metzner</surname><given-names>A</given-names></string-name>, <string-name><surname>Ouyang</surname><given-names>F</given-names></string-name>, <string-name><surname>Chun</surname><given-names>KRJ</given-names></string-name><etal>et al</etal></person-group><article-title>Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation</article-title>. <source>N Engl J Med</source><year>2016</year>;<volume>374</volume>:<fpage>2235</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">27042964</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
